Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: ImmuCell develops, acquires, manufactures, and sells products to improve the health and productivity of cows for the dairy and beef industries. Key products include First Defense® and Wipe Out® Dairy Wipes. The company operates in a single reportable segment.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2005 | Six Months Ended June 30, 2004 |
|---|---|---|
| Total Revenues | $2,580,018 | $1,907,018 |
| Net Income | $338,716 | $114,136 |
| Net Income Per Share (Diluted) | $0.11 | $0.04 |
| Operating Cash Flow | $442,704 | $237,685 |
| Cash and Short-Term Investments | $4,925,205 | $4,450,163 |
| Working Capital | $5,532,612 | $4,997,907 |
| Debt | $0 (No outstanding bank debt) | $0 |
| Gross Margin (Product Sales) | 60% | 59% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 35% ($673,000) year-over-year for the six-month period. Product sales rose 22% to $2.28 million.
- Profitability: The company reported a net income of $339,000 for the six months ended June 30, 2005, compared to $114,000 in the prior year period. This represents a significant improvement in earnings per share.
- Technology Rights Revenue: A major driver of revenue growth was the recognition of $247,000 in revenue from the sale of technology rights, stemming from a $1.5 million upfront payment received from Pfizer in December 2004. No such revenue was recognized in the comparable 2004 period.
- Expense Increases: Research and development (R&D) expenses increased 22% to $567,000, largely due to $159,000 in amortization of an intangible asset related to the Mast Out® license buyout. General and administrative expenses rose 15% to $357,000.
- Liquidity: Cash and short-term investments increased by 11% ($475,000) to nearly $5 million. Net working capital increased by 11% to $5.53 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Pfizer Partnership: The company is heavily reliant on the product development and marketing agreement with Pfizer for Mast Out®. ImmuCell has completed its obligation to supply clinical trial material for the first half of 2005. Future revenue depends on contingent milestone payments (e.g., $250,000 for patent filing in late 2005) and royalties.
- Capital Resources: Management believes current capital resources are sufficient to meet working capital requirements and finance operations for at least the next twelve months.
- Product Pipeline: The company is exploring improvements to its product line, including treatments for scours in calves and new udder sanitization formulations. It also holds an exclusive distribution agreement for the Crypto-Scan® water diagnostic test in the EU, Japan, and Australia.
Risks and Contingencies
- Regulatory Risk: Sales of First Defense® depend on USDA license approval and the stability of the Reference Standard. Wipe Out® Dairy Wipes are currently sold under an FDA compliance policy guide but may face future New Animal Drug Application (NADA) requirements that could impact profitability.
- Market Risk: The U.S. dairy industry faces economic pressure, forcing small producers out of business, which impacts the customer base. Additionally, the company is dependent on a single manufacturing facility in Portland, Maine.
- Key Personnel: As a small company with approximately 25 employees, the loss of key personnel could adversely affect operations.
- Stock-Based Compensation: The company currently uses the intrinsic value method (APB 25) for stock-based compensation. Implementation of FAS 123R (fair-value method) is required starting January 1, 2006, which will likely reduce reported net income.
Investor Verification Checklist
- Pfizer Milestone Timing: Verify the specific conditions and timelines for the $250,000 patent filing milestone and the $500,000 manufacturing transfer milestone.
- Regulatory Status of Wipe Out®: Monitor FDA guidance regarding the potential requirement for NADA approval for teat dips and udder washes.
- Customer Concentration: Note that Walco International, Inc. accounted for 18% of total product sales in the six-month period; assess the stability of this relationship.
- Impact of FAS 123R: Review the pro forma impact of the new stock-based compensation accounting standard, which reduced pro forma net income by $9,226 for the six months ended June 30, 2005.
- Deferred Revenue Recognition: Confirm the amortization schedule for the $1.5 million Pfizer payment, which is being recognized through December 31, 2007.